Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2016 - 2025)

Fate Therapeutics' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $318.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 27.63% year-over-year to $318.9 million; the TTM value through Dec 2025 reached $1.4 billion, down 29.57%, while the annual FY2025 figure was $318.9 million, 27.63% down from the prior year.
  • Liabilities and Shareholders Equity reached $318.9 million in Q4 2025 per FATE's latest filing, down from $343.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q1 2021 to a low of $318.9 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $641.0 million, with a median of $577.3 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 224.94% in 2021, then plummeted 30.57% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $921.5 million in 2021, then decreased by 23.43% to $705.6 million in 2022, then dropped by 28.25% to $506.2 million in 2023, then dropped by 12.94% to $440.7 million in 2024, then dropped by 27.63% to $318.9 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Liabilities and Shareholders Equity are $318.9 million (Q4 2025), $343.7 million (Q3 2025), and $371.6 million (Q2 2025).